The latest National Comprehensive Cancer Network (NCCN) Guidelines recommend gefitinib, lcotinib, erlotinib, and afatinib as the first-line treatment for stage IV NSCLC positive for epidermal growth factor receptor (EGFR) mutation. Here, EGFR is linked to non-small cell lung carcinoma.